Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01458288 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
A Phase 2 study of Multiple Myeloma and Non-Hodgkin's Lymphoma, sponsored by GPCR Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01458288 is a Phase 2 study of Multiple Myeloma and Non-Hodgkin's Lymphoma that has completed, run by GPCR Therapeutics. The registered enrollment target is 12 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01458288, a Phase 2 study of Multiple Myeloma and Non-Hodgkin's Lymphoma, has completed, sponsored by GPCR Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This Phase II study is to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 alone or in combination with G-CSF in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease.
Conditions Studied
Interventions
- DRUG TG-0054
Study Locations (1)
New York
- Stony Brook University Hospital - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01458288
The ClinicalTrials.gov registry entry for NCT01458288 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (98% lower). The listed sponsor is GPCR Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which TG-0054 is the first listed.
NCT01458288 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01458288 about?
NCT01458288 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease". This Phase II study is to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 alone or in combination with G-CSF in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease.
What is the current status of trial NCT01458288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2012-10. Estimated completion is 2013-07.
What conditions does trial NCT01458288 study?
This clinical trial studies the following conditions: Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's Disease.
What interventions are being tested in trial NCT01458288?
The interventions under investigation include: TG-0054 (DRUG).
Who is sponsoring clinical trial NCT01458288?
This trial is sponsored by GPCR Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01458288 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.